Connect with us

BioPharma

PHI Group, Inc. (OTCMKTS: PHIL) Curled Tight and on Watch for Reversal as M&A Player Makes Significant Progress (Update on Neok Financial & Haj Finance Group Funding)

Published

on

PHI Group, Inc. (OTCMKTS: PHIL) a major reversal could be in the works as the stock hits new 52-week lows and threatens to move into the triple zeroes. PHIL still has a massive international following who are ready to buy in large numbers whenever PHIL shows any signs of a reversal. While there are a lot of exciting things happening, PHIL speculators are wondering what happened to the $3.5 billion in funding according to the two 8k’s filed earlier this year; the Company signed a loan agreement deed with Neok Financial Incorporated, of United Arab Emirates for a loan program in the amount of $2,000,000,000 which carries a fixed preferred rate of annual interest for thirty-five years, to be repaid on a monthly basis over a period of 420 months. The Company also signed a contract agreement with Haj Finance Group, registered in Oman for a financing program in the amount of $1,500,000,000 which carries a fixed preferred rate of annual interest for thirty-five years with a three-year grace period. The closing of this transaction is to occur after the registration of a Special Purpose Vehicle (SPV) within United Arab Emirates, the signing of the closing documents and the approval of the transfer of funds by the Central Bank of United Arab Emirates (CBUAE). PHIL intends to use the funds for the establishment of the Asia Diamond Exchange and the Multi-Commodities Center in Vietnam. However as of now the Company has not received the funds for its ambitious Asia Diamond Exchange Project. 

PHIL has been busy even as the stock has been dropping, as we have said PHIL is due for a reversal here; the Company held a ZOOM PHI Group Shareholder Update Conference Call on April 22 at 4:30 P.M. EST to discuss the above topics in greater detail as well as the Company’s convertible notes, financial and operational plans, and other areas of interest.  Also, contrary to some rumors and speculations, the Company has no plan to effectuate a reserve split of its stock. Just over the past 3 weeks PHL signed an MOU with Material One-Member Ltd. Co. No. 27 “(“COMA27”), subsidiary Empire Spirits will be launching the first U.S. distilled USDA organic baijiu, a joint venture with Five-Grain Treasure Spirits Co., Ltd., (“Five-Grain”). Management has been working hard to get the financial audits of Vinafilms completed however this has taken longer than anticipated. Also, this past week subsidiary (www.co2-1-0.io), reported the listing of CO2-1-0 (CARBON) CORP, a subsidiary of the Company, on DigiFinex Digital Assets Exchange (https://www.digifinex.com/en-ww/) Will become effective at 11:00 AM Singapore time (GMT+8) on Friday April 22, 2022. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

PHI Group, Inc. (OTCMKTS: PHIL) is a diversified holding company currently engaged in PHILUX Global Funds, a group of Luxembourg bank funds organized as “Reserved Alternative Investment Fund” (“RAIF”), and the Asia Diamond Exchange (“ADE”) project in Vietnam. The Company also engages in mergers and acquisitions and invests in select industries and special situations that may substantially enhance shareholder value. Microcapdaily has written about PHIL many times with different articles based on different aspects of the Company, you can find all PHIL articles on the website on the homepage, just put PHIL in the search field. 

In August of last year CEO Henry Fahman substantially increased his stock ownership in the Company. On August 19, 2021 Henry Fahman converted $500,000 of the loan that he made to PHI Group on 02/07/2020 into 103,279,112 shares of restricted Common Stock of PHI Group, Inc. to increase his direct ownership in the Company. A Form 4 will be filed with the Securities and Exchange Commission to report the transaction. 

PHI Group has been busy although this has not been reflected in the stock price; PHI LUXEMBOURG DEVELOPMENT S.A., a wholly-owned subsidiary of the Company, which serves as the mother holding company for PHILUX GLOBAL FUNDS, has signed a Memorandum of Agreement with “Building and Construction Material One-Member Ltd. Co. No. 27 “ (“COMA27”), a company belonging 100% to the Ministry of Construction of Vietnam, for COMA27 to participate in the Public Private Partnership (PPP) with PHILUX Asia Diamond Center Development Fund in order to organize the Asia Diamond Exchange in the Free-trade Zone of the Chu Lai Open Economic Zone, Quang Nam Province, Vietnam.  The Company has been working diligently to set up a diamond exchange in Vietnam according to the model of Dubai’s DMCC https://www.dmcc.ae/. 

The Asia Diamond Exchange is a modern bourse to be established in affiliation with the World Federation of Diamond Bourses (WFDB). It will be the first-ever vital rough diamond exchange in Asia, comparable to the diamond exchanges in Antwerp (Belgium)  and Dubai (UAE). The Company has launched an ADE token in South Korea in connection with the Asia Diamond Exchange. The token is designed to optimize transparency and fair pricing to the diamond industry to provide enhanced benefits to all stakeholders. By validating transactions on a blockchain, there are no chances of counterfeiting or substandard pieces. Consumers will be able to design and purchase custom diamond jewelry and loose gemstones at significantly better prices by using the ADE tokens. The ADE tokens will be deflationary by setting aside profits to purchase and burn tokens as well as systematically continuing the buy-back of PHIL stock on an ongoing basis in the future. International investors may purchase and trade the tokens once they are listed on top exchanges such as Coinbase and Binance. 

To Find out the inside Scoop on PHIL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PHIL

The financial audits of Vinafilms have taken longer than anticipated due to additional work associated with a previous merger between Vinafims and another local plastic manufacturing company. PHI Group’s auditor Dylan Floyd Accounting & Consulting has recently engaged ASC Auditing Company Limited to assist in the audit process and expects to finish the audits of Vinafilms’ financial statements in time to allow PHI Group to consolidate Vinafilms’ operating results with those of PHI Group for the quarter ending March 31, 2019. PHI Group is also awaiting the results of an independent valuation of Saigon Pho Palace JSC in order to close the acquisition of a majority interest in this company.  PHI Group will be able to consolidate operating results of Saigon Pho Palace JSC after the GAAP audits of Saigon Pho Palace’s financial statements are finished. 

The Company’s subsidiary Empire Spirits will be launching the first U.S. distilled USDA organic baijiu, a joint venture with Five-Grain Treasure Spirits Co., Ltd., (“Five-Grain”), a company with over one hundred years of tradition in Jilin Province, China. The product will mark the first in a series of ultra-premium organic baijiu spirits to be distilled in the United States. Baijiu, a white spirit distilled from sorghum, similar to vodka but with a fragrant aroma and taste, is the world’s most consumed spirit that boasts sales of over USD 83 billion. Priced up to 10X that of a similarly aged Scotch Whiskey, baijiu is considered the king of all spirits. 

On April 21 PHIL subsidiary (www.co2-1-0.io), reported the listing of CO2-1-0 (CARBON) CORP, a subsidiary of the Company, on DigiFinex Digital Assets Exchange (https://www.digifinex.com/en-ww/) will become effective at 11:00 AM Singapore time (GMT+8) on Friday April 22, 2022. 

CO2-1-0 (CARBON) CORP. (https://CO2-1-0.io) Aims to provide a solution in disruptive new carbon market (voluntary and compliancy market) using blockchain-crypto technology, Internet of Things (IoT), and Six Sigma (6σ) methodology, which will empower the real environmentally sustainable projects (renewable energy, energy savings, heat recovery, industrial waste, agriculture, forestry, and many other new technologies), which projects have started in the USA, Vietnam, Indonesia, other ASEAN countries, and worldwide. It has a clear and systematic product development roadmap, and the ultimate milestones of the products. The solution, methodology, and improved TACCC (transparent, accurate, consistent, complete, and comparable) business process originally introduced by CO2-1-0 (CARBON) will bring full impact to better environment and life of millions. 

https://twitter.com/Jeannot95460341/status/1517132033696288770

For more on PHIL Subscribe Right Now!

Currently trading at a $35 million market valuation PHIL has 29,877,933,513 shares outstanding, some convertible debt on the books and just over $4 million in assets and minimal revenues to date. While the Company continues to announce exciting initiatives such as launching the first U.S. distilled USDA organic baijiu, a joint venture with Five-Grain Treasure Spirits Co., Ltd., or the MOU with Solar EVN Ngoc Chau to cooperate in a new disruptive carbon mitigation program. PHIL has continued to fall as investors wait on news of the $3.5 billion in funding according to the 2 8k filed earlier this year that PHIL plans to use to build its ambitious Asia Diamond Exchange Project. PHIL does have a massive international following who are ready to buy in large numbers in PHIL, once the reversal starts, it’s a long way back to the highs of $0.098 last summer. We will be updating on PHIL so make sure you Subscribe to Microcapdaily so you know what’s going on with PHIL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PHIL either long or short and we have not been compensated for this article.

Continue Reading
2 Comments

2 Comments

  1. John Dutkiewicz

    June 2, 2022 at 7:26 pm

    Since this article was published, no VF audit has been included in Phils’ 10q. Also both loans of which you speak has been terminated. And the SP of Phil has done nothing but tank. Why haven’t you updated us on that info?

    • Boe Rimes

      June 4, 2022 at 12:36 am

      Hi John,
      We will do an article on PHIL over the weekend. Check the website Sunday evening.
      cheers, Boe

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.